Fenofibrate and atherogenic dyslipidemia

Juan Pedro-Botet, Juana A. Flores-Le Roux

Research output: Contribution to journalArticleResearchpeer-review


The first intervention studies of fibrates for the prevention of coronary heart disease were performed in 1971. The meta-analyses and systematic reviews published in the last 5 years confirm that fibrates reduce cardiovascular risk, especially in the presence of atherogenic dyslipidemia. This pattern of dyslipidemia, which causes hypertriglyceridemia, low levels of high-density lipoprotein (HDL) cholesterol and a predominance of small, dense low-density lipoprotein (LDL) particles, is often observed in type 2 diabetes and metabolic syndrome. The present article discusses the macroangiopathic results of the three main studies of fenofibrate in patients with type 2 diabetes: one study of progression/regression of coronary atherosclerosis (DAIS) and two with clinical aims (FIELD and ACCORD). Analysis of these studies provides information on a more appropriate approach to diabetic patients and clearly shows that those who could benefit from fenofibrate therapy are patients with atherogenic dyslipidemia rather than the entire diabetic population. Therefore, it is essential to highlight the importance of establishing and reaching therapeutic targets not only in LDL-cholesterol but also in HDL-cholesterol and triglycerides. © 2012 Sociedad Española de Arteriosclerosis y Elsevier España S.L.
Original languageEnglish
Pages (from-to)24-28
JournalClinica e Investigacion en Arteriosclerosis
Issue numberSUPPL. 1
Publication statusPublished - 1 Jul 2012


  • Atherogenic dyslipidemia
  • Cardiovascular disease
  • Diabetes
  • Fenofibrate


Dive into the research topics of 'Fenofibrate and atherogenic dyslipidemia'. Together they form a unique fingerprint.

Cite this